Freenome

Categories

Description

An intelligent screening platform that uses multiomics technology for early cancer detection.

Summary

Freenome leverages advanced multiomics technology and artificial intelligence to enhance early cancer detection through standard blood draws. Its platform is designed to identify cancer at its most treatable stages, supported by a rigorous clinical program that drives the discovery, development, and validation of its early detection tests. This approach aims to significantly improve patient outcomes by facilitating earlier and more accurate cancer diagnosis.

Use Cases

• Clinicians use Freenome's platform to detect early-stage cancers through a simple blood test.
• Researchers leverage Freenome's technology to explore new biomarkers for cancer detection.